AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This latest payout marks a significant milestone: the company's 348th consecutive quarterly dividend. The unwavering consistency of
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This payment marks a significant milestone as the company's 348th consecutive quarterly dividend, a testament to its
Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential
On a day where the broader S&P 500 and Nasdaq Composite indices soared to new all-time record highs, the S&P 500 Healthcare sector presented a compelling, albeit nuanced, narrative of market leadership and resilience. While the overall market sentiment exuded robust optimism, the healthcare sector itself showcased a
Discover three standout growth stocks with strong long-term potential, spanning space, retail, and biotech industries, poised for sustained investor returns
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped returns as the industry’s six-month gain of 6.5% has lagged the S&P 500’s 24.7% climb.
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
Stay tuned for the market movements in the S&P500 index on Thursday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government shutdown and a disappointing jobs report. As investors sought refuge in defensive plays and reacted to
Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 5.2% in the afternoon session after the company submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for its drug candidate pivekimab sunirine. The company is developing the molecule as a potential treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and highly aggressive blood cancer, as well as acute myeloid leukemia (AML). Investor optimism was further bolstered by AbbVie's announcement of a $70 million expansion of its Bioresearch Center in Massachusetts to increase its U.S. biologics manufacturing and R&D capabilities. This move is part of a larger investment to strengthen domestic operations, potentially shielding the company from pharmaceutical tariffs. The positive news, which followed the stock reaching an all-time high on the previous day, appeared to outweigh a downgrade from HSBC to 'Hold' from 'Buy'.
The global healthcare sector is currently navigating a period of profound transformation, driven by aggressive regulatory changes emanating from the United States. As of late September 2025, a series of White House initiatives and legislative actions, most notably the ongoing implementation of the Inflation Reduction Act (IRA) and the pursuit
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a broader market optimism rippling through the healthcare sector. While AMN's direct stock drivers often stem from company-specific operational successes, today's surge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing agreement reached between the White House and a major pharmaceutical player, Pfizer (NYSE: PFE). This development has been widely interpreted by investors as
